-
Mashup Score: 0High cost and demand for old cancer drug sparks crisis - 1 year(s) ago
Experts have voiced alarm at the scarcity and cost of fludarabine, an old drug deemed crucial to cellular therapy for leukemia.
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Fludarabine shortage requires flexibility, alternative approaches for CAR-T and HSCT - 1 year(s) ago
For the second time in the last 2 years, a drug related to the administration of cellular therapy — fludarabine — has been placed on the FDA’s drug shortage list. The FDA first noted the fludarabine shortage in May, with four of its manufacturers reporting either backordered or limited supplies available as of October.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3ASTCT Learning Center: ASTCT 2022 National Fludarabine Shortage for HCT and CAR-T Cell Recipients: Frequently Asked Questions - 1 year(s) ago
ASTCT 2022 National Fludarabine Shortage for HCT and CAR-T Cell Recipients: Frequently Asked Questions Open to download resource.
Source: learn.astct.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0ASTCT Fludarabine Shortage Survey - 1 year(s) ago
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Source: www.surveymonkey.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 9ASTCT Learning Center: ASTCT 2022 National Fludarabine Shortage for HCT and CAR-T Cell Recipients: Frequently Asked Questions - 1 year(s) ago
These are the ASTCT 2022 National Fludarabine Shortage for HCT and CAR-T Cell Recipients: Frequently Asked Questions.Please complete this optional survey regarding the shortage here: https://www.surveymonkey.com/r/93Q293C. …
Source: learn.astct.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Oral and Poster Abstracts 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I Clinical Trials, Biological therapies, Adults, Workforce, Diversity, Equity, Inclusion, and Accessibility (DEI/DEIA) , Pediatric, Therapies, Study Population, Transplantation Najla H El Jurdi, MD1, Daniel O’Leary, MD2, Fiona He, MD3, Todd E….
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Hematopoietic Cell Transplantation and Cell therapy weekly newsletter 14/04/2022- Issue #4 - 2 year(s) ago
THIS WEEK at a glance:CART and IFNgammaR pathway for solid tumorsTisacel has 50% CR for primary CNVS lymphomaInfectious complications after anti-BCMA CARTsFludarabine exposure and CART efficacy for leukemiaMachine learning score to predict allogeneic donor mobilizationSocial and racial disparities matter in CART therapy access
Source: www.getrevue.coCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 1JNCCN 360 - CLL - Phase II Trial Focuses on Short-Course Fludarabine With Continuous Ibrutinib in CLL - 3 year(s) ago
By: Kelly M. Hennessey, PhD Posted: Wednesday, November 4, 2020 Ibrutinib in combination with a short course of fludarabine led to a higher complete response than traditional therapeutics in patients with treatment-naive chronic lymphocytic leukemia (CLL), based on the findings of a phase II trial. Inhye E….
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0JNCCN 360 - 4 year(s) ago
By: Lauren Harrison, MS Posted: Wednesday, June 17, 2020 The 1-year overall survival among elderly patients with acute myeloid leukemia (AML) appears to be prolonged with azacitidine compared with fludarabine plus cytarabine; however long-term outcomes are poor with both treatment protocols. Susana Vives Polo,…
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
#High cost and demand for old #CancerDrug sparks crisis 👉https://t.co/mYKsv0hK9q @MDedgeHemOnc @DotingaRandy #Fludarabine https://t.co/pVY97RvtJE